{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:10:22Z","timestamp":1778685022312,"version":"3.51.4"},"reference-count":20,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,4,24]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>A man in his early 80s presented with transfusion-dependent macrocytic anaemia, steroid-responsive headaches and recurrent inflammatory flares. Broad infectious, autoimmune and haematological investigations were negative, yet symptoms relapsed each time prednisolone was tapered. The coexistence of refractory inflammation, giant cell arteritis-like features and progressive cytopenias prompted targeted sequencing, which uncovered a somatic UBA1 p.Met41Thr mutation and confirmed vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Empirical antimicrobials and high-dose steroids provided only brief control. Ruxolitinib followed by subcutaneous azacitidine stabilised inflammatory markers, enabled gradual steroid tapering and reduced hospitalisations although anaemia remained. This case highlights key diagnostic and management principles. First, clinicians should consider VEXAS in older men with overlapping vasculitic and myelodysplastic features. Second, molecular testing should be pursued even when marrow vacuoles are subtle. Thirdly, multidisciplinary care combining steroid-sparing immunomodulators with clonal-directed therapy is essential.<\/jats:p>","DOI":"10.1136\/bcr-2025-271503","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:20:29Z","timestamp":1778682029000},"page":"e271503","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic inflammation with myelodysplastic features: VEXAS syndrome"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-2173","authenticated-orcid":false,"given":"Mohamed M","family":"Khamis","sequence":"first","affiliation":[{"name":"Internal Medicine, Mercy Hospital St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqra M","family":"Bhatti","sequence":"additional","affiliation":[{"name":"Internal Medicine, Mercy Hospital St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepthi","family":"Busayavalasa","sequence":"additional","affiliation":[{"name":"David M. Sindelar Cancer Centre - South St. Louis, Mercy Hospital South, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051307200849000_19.5.e271503.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026834"},{"key":"2026051307200849000_19.5.e271503.2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20805"},{"key":"2026051307200849000_19.5.e271503.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24836"},{"key":"2026051307200849000_19.5.e271503.4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood.2024028133","article-title":"Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX","volume":"146","author":"Jachiet","year":"2025","journal-title":"Blood"},{"key":"2026051307200849000_19.5.e271503.5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/BOR.0000000000001068","article-title":"VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation","volume":"37","author":"K\u00f6tter","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"2026051307200849000_19.5.e271503.6","unstructured":"Hadjadj J , Beck D . VEXAS syndrome. In: Adam MP , Bick S , Mirzaa GM , et al ., eds. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle, 2025."},{"key":"2026051307200849000_19.5.e271503.7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/art.41743","article-title":"Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS","volume":"73","author":"Ferrada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026051307200849000_19.5.e271503.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.14578"},{"key":"2026051307200849000_19.5.e271503.9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13041049","article-title":"VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge","volume":"13","author":"Kreutzinger","year":"2024","journal-title":"J Clin Med"},{"key":"2026051307200849000_19.5.e271503.10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/ajcp\/aqad186","article-title":"Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients","volume":"161","author":"Olteanu","year":"2024","journal-title":"Am J Clin Pathol"},{"key":"2026051307200849000_19.5.e271503.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2021.10.007"},{"key":"2026051307200849000_19.5.e271503.12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/art.43287","article-title":"American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel","volume":"78","author":"Mekinian","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"2026051307200849000_19.5.e271503.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354130","article-title":"Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort","volume":"15","author":"Diral","year":"2024","journal-title":"Front Immunol"},{"key":"2026051307200849000_19.5.e271503.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead240"},{"key":"2026051307200849000_19.5.e271503.15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ard.2025.05.021","article-title":"Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies","volume":"85","author":"Turturice","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026051307200849000_19.5.e271503.16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00296-023-05513-0","article-title":"Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review","volume":"44","author":"Kouranloo","year":"2024","journal-title":"Rheumatol Int"},{"key":"2026051307200849000_19.5.e271503.17","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(25)00034-7"},{"key":"2026051307200849000_19.5.e271503.18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.19953","article-title":"Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics","volume":"206","author":"\u00c1lamo","year":"2025","journal-title":"Br J Haematol"},{"key":"2026051307200849000_19.5.e271503.19","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s00277-024-05942-2","article-title":"Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome","volume":"103","author":"Dias","year":"2024","journal-title":"Ann Hematol"},{"key":"2026051307200849000_19.5.e271503.20","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood.2025029732","article-title":"Azacitidine as therapy for VEXAS syndrome","volume":"146","author":"Steensma","year":"2025","journal-title":"Blood"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:20:34Z","timestamp":1778682034000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bcr-2025-271503"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271503","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}